RUA Life Sciences - Cancellation & Reissue Share Options

Rua Life Sciences

10/12/2025 14:55

RNS Number : 0622L

RUA Life Sciences PLC

10 December 2025

 

10 December 2025

 

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Cancellation & Reissue Share Options, PDMR Notice

RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), announces that it has today cancelled, for nil consideration, certain options previously granted on 19 June 2024.

An administrative oversight following grant resulted in such options failing to be registered for EMI.  The board have therefore agreed to rectify this through the cancellation and re-grant, to put the employees in no worse position than they would have been.

An equivalent number of new options have therefore been granted over ordinary shares of 5 pence each in the Company ("Options") under the Enterprise Management Incentive (EMI) share option scheme.  The number, exercise price and the vesting terms and conditions of the new Options are the same as the options cancelled.

A total of 2,900,000 EMI Options have been granted, allocated as follows:

Name
Options cancelled (19 June 2024 Grant)
Options Granted (re-Grant)
Plan
Exercise price
William Brown
1,400,000
1,400,000
EMI
11 pence
Lachlan Smith
1,200,000
1,200,000
EMI
11 pence
Other employees
300,000
300,000
EMI
11 pence

 

Vesting and exercise

 

·      Options vest on 19 June 2027 (three years after original grant) and are exercisable up to the plan long-stop (10 years from original grant).

·      In the event of an offer to acquire the whole company prior to the plan long-stop date, vesting may accelerate in accordance with plan rules.

·      If a return of capital is proposed at an amount per share that is greater than the exercise price per share of these options, they will vest immediately prior to such return of capital to allow option holders to participate.

 

Following the cancelation and issuance of these share options, the Company had and will continue to have 5,625,603 shares under option being 9 % of the issued share capital of the Company.

 

For further information contact:

 

RUA Life Sciences
Bill Brown, Chairman
Lachlan Smith, CFO
Tel: +44 (0)1294 317073
Tel: +44 (0)1294 317073
Cavendish Capital Markets Limited
(Nominated Adviser and Broker)
Giles Balleny/Isaac Hooper (Corporate Finance)
Harriet Ward (Broking)
Nigel Birks (Healthcare Specialist Sales)
Michael Johnson (Sales)
Tel: +44 (0)20 7220 0500

  

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
1. William Brown
2. Lachlan Smith
2
Reason for the notification
a)
Position/status
1. Chief Executive Officer
2. Chief Financial Officer
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Rua Life SciencesPlc
b)
LEI
213800BMVB22PVOJ9Z28
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Options over Ordinary Shares of £0.05 each
Identification code
ISIN: GB0033360586
b)
Nature of the transaction
Grant and cancellation of options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1.
£0.11 (Grant)
1,400,000
£0.11 (Cancellation)
1,400,000
2.
£0.11 (Grant)
1,200,000
£0.11 (Cancellation)
1,200,000
d)
Aggregated information
- Aggregated volume
N/A
- Price
N/A
e)
Date of the transaction
10 December 2025
f)
Place of the transaction
Outside a trading venue


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHFFFFLSEISEIE